2010 Fiscal Year Final Research Report
Development of new anti-cancer agents for ovarian cancer
| Project/Area Number |
20591935
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
YOKOYAMA Yoshihito Hirosaki University, 大学院・医学研究科, 講師 (90261453)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 卵巣癌 / 抗腫瘍剤 / クロフィブリン酸 / Carbonyl reductase / 光線力学的療法 / アミノレブリン酸メチルエステル塩酸塩 / プロトポルフィリンIX / プロスタグランディンE_2 |
|---|
| Research Abstract |
Clofibric acid, a peroxisome proliferator-activated receptor α ligand, inhibits proliferation of ovarian cancer by decreasing prostaglandin (PG) E_2 activity through induction of carbonyl reductase (CR), a PGE_2-converting enzyme, in tumor. The tumor volume of the CR induction group increased up to the 2nd week but then decreased continually until the 5th week of observation. Increased necrosis due to phagocytosis of apoptotic cells by phagocytes attracted by increased Milk fat globule EGF factor 8 was considered to be the mechanism of spontaneous tumor regression in the CR induction group. Also, photodynamic therapy of a methyl ester of 5-aminolevulinic acid significantly suppressed the growth of HTOA tumors as compared to control.
|
